Shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) plunged 5.58% in pre-market trading on October 31, 2024, following the company's third-quarter financial results and a strategic shift in its business focus.
The biopharmaceutical company reported quarterly losses of $0.82 per share, beating the analyst consensus estimate of $0.84 by 2.38%. However, its revenue of $3.74 million missed the analyst consensus estimate of $10.36 million by a significant 63.9%, representing a 20.9% year-over-year decrease.
In a separate announcement, Kymera unveiled plans to shift its focus and resources from oncology to its expanding immunology pipeline. The company stated that it would only advance its two oncology candidates, KT-333 (STAT3) and KT-253 (MDM2), beyond Phase 1 with a partner. Additionally, Kymera selected a new immunology candidate, KT-295, a TYK2 degrader, to advance into a Phase 1 clinical trial in the first half of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.